CPA
IDYA icon

Capital Performance Advisors’s IDEAYA Biosciences IDYA Stock Holding History

Capital Performance Advisors’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$32 – 1322
2024
Q3 		$32 Buy
+1
New +$38 ﹤0.01% 2833

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital Performance Advisors's IDYA Position: Q4 2024 in Review

Capital Performance Advisors sold out of IDEAYA Biosciences (IDYA) in Q4 2024, closing a stake of 1 share — an estimated $32 sold.

Capital Performance Advisors first reported a position in IDYA in Q3 2024 and held it in 1 quarter. The position peaked at $32 in Q3 2024. 206 funds tracked by Wall St. Rank hold IDYA as of Q4 2024.

  • Capital Performance Advisors reported no remaining IDEAYA Biosciences position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 1 IDEAYA Biosciences share in Q4 2024, an estimated $32.
  • Capital Performance Advisors first reported a position in IDEAYA Biosciences in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's IDEAYA Biosciences position peaked at $32 in Q3 2024.
  • 206 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.